ライフサイエンスコーパス: cytoreductive

1 Interestingly, potent cytoreductive activity was demonstrated in a gastric car

2 well as our approach to choosing a specific cytoreductive agent and how to effectively monitor treat

3 ditional predictive factors were exposure to cytoreductive agents for leukemic transformation (OR = 3

4 including anti-mast cell mediator drugs, and cytoreductive agents for patients with advanced disease

5 ment of proliferative CMML usually relies on cytoreductive agents such as hydroxyurea, although ongoi

6 idly and expand their numbers in response to cytoreductive agents, such as cyclophosphamide (CY), and

7 interferons remain the preferred first-line cytoreductive agents, with the JAK1 and JAK2 inhibitor,

8 or with a history of thrombosis) are offered cytoreductive agents.

9 hat could potentially be achieved with local cytoreductive and/or metastasis-directed therapies.

10 cy at well-tolerated doses, including marked cytoreductive antitumor activity, in several tumor model

11 ents treated with neoadjuvant intra-arterial cytoreductive chemotherapy (IACC), orbital exenteration,

12 f giving uniform dose-dense and dose-intense cytoreductive chemotherapy and integrating accelerated f

13 The standard-of-care cytoreductive chemotherapy depletes AML cells to induce

14 However, little is known about the impact of cytoreductive chemotherapy on HIV-1 reservoir dynamics,

15 topoietic stem cell transplantation combines cytoreductive chemotherapy with adoptive immunotherapy a

16 Despite cytoreductive chemotherapy, plasma uric acid concentrati

17 d returned to the patients without preceding cytoreductive chemotherapy.

18 epithelial cell integrity in the presence of cytoreductive chemotherapy.

19 f late B7 vaccines in combination with prior cytoreductive chemotherapy.

20 te minimal residual neoplastic disease after cytoreductive chemotherapy.

21 tress, pregnancy, malnutrition, drug use and cytoreductive chemotherapy.

22 BMT) has been limited by toxicity related to cytoreductive conditioning and immune response.

23 ene therapy and underscore the importance of cytoreductive conditioning in this type of gene therapy

24 imerism and donor-specific tolerance without cytoreductive conditioning or immunosuppression.

25 cific hyporesponsiveness in the absence of a cytoreductive conditioning regimen.

26 or CAR-engineered HSCs would likely require cytoreductive conditioning to achieve long-term engraftm

27 etic stem cell transplantation without prior cytoreductive conditioning, although the mechanism of im

28 transplant SCID patients without the use of cytoreductive conditioning, but it is clear that this is

29 In the absence of irradiation or other cytoreductive conditioning, endogenous hematopoietic ste

30 f normal congenic bone marrow, without prior cytoreductive conditioning, which resulted in long-term

31 nction is severely compromised due to age or cytoreductive conditioning.

32 nsplanted donor HSCs, even in the absence of cytoreductive conditioning.

33 e status of > or = 60% who were eligible for cytoreductive craniotomy were enrolled.

34 Hydroxycarbamide (HC, hydroxyurea) is a cytoreductive drug inducing cell cycle blockade.

35 pirin, either alone or in combination with a cytoreductive drug such as hydroxyurea.

36 had previous thrombotic events should start cytoreductive drug therapy if at least one of the follow

37 Low-dose aspirin and cytoreductive drugs can be administered to this purpose,

38 Currently used cytoreductive drugs include hydroxyurea, mainly used in

39 gens, or immunomodulatory agents for anemia, cytoreductive drugs such as hydroxyurea for the splenome

40 Children with ST received more cytoreductive drugs than those with HT (P = .0006).

41 a s.c. A549 lung cancer xenograft model, the cytoreductive effect of Ad.TK(RC)(II) was enhanced when

42 In contrast, the cytoreductive efficacy of the replication-competent vect

43 y combining such forms of therapy with other cytoreductive measures including surgery.

44 ated genome-wide H3K36me3 profiles from four cytoreductive nephrectomies and SETD2 isogenic renal cel

45 The role of cytoreductive nephrectomy (CN) in metastatic renal cell

46 bining tyrosine kinase inhibitors (TKIs) and cytoreductive nephrectomy (CN) in patients with metastat

47 ted a significant OS benefit associated with cytoreductive nephrectomy (multivariable Cox proportiona

48 imilar to that of M-LR patients treated with cytoreductive nephrectomy and adjuvant IMT.

49 operative pazopanib therapy prior to planned cytoreductive nephrectomy and continued pazopanib therap

50 s did not demonstrate an association between cytoreductive nephrectomy and OS (HR, 0.92; 95% CI, 0.78

51 a method to select appropriate patients for cytoreductive nephrectomy are warranted.

52 patients who are most likely to benefit from cytoreductive nephrectomy but also allows access to trea

53 nstrate a survival advantage associated with cytoreductive nephrectomy for patients with metastatic c

54 The timing of cytoreductive nephrectomy has also been controversial an

55 Cytoreductive nephrectomy has an established role in man

56 omy, and limited available evidence supports cytoreductive nephrectomy in appropriately selected pati

57 trate an overall survival (OS) advantage for cytoreductive nephrectomy in patients with metastatic cl

58 Importance: The role of cytoreductive nephrectomy in patients with metastatic re

59 ficacy of upfront pazopanib therapy prior to cytoreductive nephrectomy in previously untreated patien

60 The role of cytoreductive nephrectomy in the management of metastati

61 For these patients, the role of cytoreductive nephrectomy is disputed.

62 Additionally, cytoreductive nephrectomy is often indicated before the

63 flects the fact that surgical indication for cytoreductive nephrectomy is primarily driven by factors

64 ion, we propose that the observed effects of cytoreductive nephrectomy may be caused by resection of

65 Cytoreductive nephrectomy may be offered to select patie

66 Cytoreductive nephrectomy prior to systemic therapy sign

67 Cytoreductive nephrectomy should be considered to provid

68 Cytoreductive nephrectomy was performed in 5005 patients

69 argely been observed in the context of prior cytoreductive nephrectomy, and limited available evidenc

70 After cytoreductive nephrectomy, critical care therapy rate wa

71 inging into question the paradigm of upfront cytoreductive nephrectomy, inherited from the era of cyt

72 cessity, patient selection for and timing of cytoreductive nephrectomy.

73 ent of risk factors for complications before cytoreductive nephrectomy.

74 pha (IFN-alpha) are the most frequently used cytoreductive options for patients with ET and PV at hig

75 arding the role and outcomes of nephrectomy (cytoreductive or consolidative) in conjunction with ICI

76 In Cox regression analysis, response to cytoreductive or salvage therapy and B symptoms at relap

77 tion of remission, and favorable response to cytoreductive or salvage therapy were most predictive of

78 cer (HGSOC) and to evaluate CT indicators of cytoreductive outcome and survival in patients with BRCA

79 cal and CT features were not associated with cytoreductive outcome for patients with BRCA-mutant HGSO

80 CT indicators of cytoreductive outcome varied according to BRCA mutation

81 s between CT features, BRCA mutation status, cytoreductive outcome, and progression-free survival (PF

82 ly been demonstrated for the less completely cytoreductive pleurectomy procedure when combined with i

83 The cytoreductive potential of MV-Ed has been investigated i

84 targeted for gene transfer is facilitated by cytoreductive preconditioning such as high-dose total bo

85 These findings suggest that ultraradical cytoreductive procedures might be targeted for selected

86 The cytoreductive regimen consisted of hyperfractionated tot

87 erlying diagnoses, severe immune deficiency, cytoreductive regimen, and graft-versus-host reactions.

88 d appear to be key determinants of the early cytoreductive response to remission induction therapy an

89 e CA-125 level, surgical stage, ascites, and cytoreductive status.

90 The success of high-dose cytoreductive strategies depends not only on antitumor a

91 also discuss the current evidence base for a cytoreductive strategy, including metastasis-directed th

92 Survival based on the number of cytoreductive surgeries and the free interval between th

93 he roles of primary, interval, and secondary cytoreductive surgeries; second-look procedures; and pal

94 and tertile of program mean annual volume of cytoreductive surgery (<12.0, 12.0-23.9, or >=24.0 cases

95 apy and 0.54 (95% CI, 0.36-0.81) for primary cytoreductive surgery (all high certainty).

96 ve cure and survival rates involves complete cytoreductive surgery (CCRS) and hyperthermic intraperit

97 pectively collected data on patients who had cytoreductive surgery (CRS) and HIPEC in a single instit

98 Cytoreductive surgery (CRS) and hyperthermic intraperito

99 idity (MM) and failure-to-rescue (FTR) after cytoreductive surgery (CRS) and hyperthermic intraperito

100 valuate outcome and long-term survival after cytoreductive surgery (CRS) and hyperthermic intraperito

101 cer may be treated with a curative intent by cytoreductive surgery (CRS) and hyperthermic intraperito

102 Cytoreductive surgery (CRS) and hyperthermic intraperito

103 zed trial demonstrated a survival benefit of cytoreductive surgery (CRS) and intraperitoneal chemothe

104 etastases of colorectal cancer, treated with cytoreductive surgery (CRS) and resulting in a pathologi

105 ould impact the failure-to-rescue rate after cytoreductive surgery (CRS) for peritoneal carcinomatosi

106 Cytoreductive surgery (CRS) has emerged as a survival-ex

107 aperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery (CRS) improved recurrence-free and

108 Cytoreductive surgery (CRS) is one of the most complex o

109 Cytoreductive surgery (CRS) with hyperthermic intraperit

110 Cytoreductive surgery (CRS) yields promising results, bu

111 varian cancer who are ineligible for primary cytoreductive surgery (CRS).

112 perthermic intraperitoneal chemotherapy with cytoreductive surgery (HIPEC + CS).

113 Interval cytoreductive surgery (ICS) should be performed after <=

114 sex (P < .001), age </= 65 years (P = .005), cytoreductive surgery (P < .001), and epithelioid histol

115 ostic laparoscopy can prevent futile primary cytoreductive surgery (PCS) by identifying patients with

116 mains about the relative benefits of primary cytoreductive surgery (PCS) vs neoadjuvant chemotherapy

117 nt chemotherapy (NACT) compared with primary cytoreductive surgery (PCS).

118 e ovarian cancer may be treated with primary cytoreductive surgery (removal of all visible cancer in

119 or with neoadjuvant chemotherapy followed by cytoreductive surgery and adjuvant chemotherapy.

120 fied by a general paradigm of maximally safe cytoreductive surgery and advanced radiation delivery te

121 inical remission after completion of primary cytoreductive surgery and chemotherapy at 6 National Can

122 Cytoreductive surgery and heated intraperitoneal chemoth

123 e demonstrates the feasibility and safety of cytoreductive surgery and HIPEC via the laparoscopic rou

124 d perioperative systemic therapy relative to cytoreductive surgery and hyperthermic intraperitoneal c

125 A large proportion of patients undergoing cytoreductive surgery and hyperthermic intraperitoneal c

126 Patients with PM from CRC admitted for cytoreductive surgery and hyperthermic intraperitoneal c

127 Cytoreductive surgery and hyperthermic intraperitoneal c

128 Therefore, investigators have applied cytoreductive surgery and hyperthermic perioperative che

129 impact on progression-free survival (PFS) of cytoreductive surgery and international variations in su

130 All patients with colorectal PC referred for cytoreductive surgery and intraperitoneal chemotherapy (

131 ere managed by a treatment regimen that used cytoreductive surgery and intraperitoneal chemotherapy.

132 with PC and synchronous LM who had undergone cytoreductive surgery and LM resection followed by intra

133 ents with OvCa who underwent a diagnostic or cytoreductive surgery and nononcological patients, who u

134 with routine observation (OBS) after primary cytoreductive surgery and platinum-based chemotherapy in

135 The therapeutic value of cytoreductive surgery and radiation therapy for posterio

136 l carcinomatosis (PC) who underwent complete cytoreductive surgery and resection of LM, followed by i

137 atients with advanced-stage disease, maximum cytoreductive surgery appears to be beneficial.

138 The survival benefits of cytoreductive surgery are also applicable to women with

139 years) with abdominopelvic CT before primary cytoreductive surgery available through the Cancer Imagi

140 arian cancer who underwent CT before primary cytoreductive surgery between 1997 and 2004 (mean age, 6

141 PURPOSE OF REVIEW: Cytoreductive surgery combined with hyperthermic intrape

142 The efficacy of cytoreductive surgery combined with perioperative intrap

143 The current evidence suggests that cytoreductive surgery combined with perioperative intrap

144 as management strategies, including complete cytoreductive surgery embedded in perioperative systemic

145 he expansion of treatment options, including cytoreductive surgery followed by chemotherapy with hype

146 gical malignancy that is commonly treated by cytoreductive surgery followed by cisplatin treatment.

147 e was randomly assigned to undergo secondary cytoreductive surgery followed by three more cycles of c

148 fic immunotherapy should be considered after cytoreductive surgery for advanced melanoma.

149 Death after cytoreductive surgery for advanced-stage ovarian cancer

150 resh human tissue taken from patients during cytoreductive surgery for peritoneal metastasis of colon

151 e of HIPEC with carboplatin during secondary cytoreductive surgery for platinum-sensitive recurrent o

152 Interval cytoreductive surgery has been shown to confer a surviva

153 mic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery have been shown to benefit selecte

154 Using fluorescence-guided surgery (FGS) to cytoreductive surgery helps achieving complete resection

155 e availability of retroperitoneal staging or cytoreductive surgery if necessary.

156 ospective study of CT images obtained before cytoreductive surgery in 46 women with HGSOC, whose tumo

157 ighted the feasibility of combining ICT with cytoreductive surgery in a metastatic setting and demons

158 A new treatment strategy starts with cytoreductive surgery in an attempt to remove all visibl

159 Despite continuing debates around cytoreductive surgery in malignant gliomas, there is bro

160 However, how cytoreductive surgery in the metastatic setting modulate

161 Immune-monitoring studies demonstrated that cytoreductive surgery increased antigen-presenting dendr

162 troy small residual mucinous tumour nodules, cytoreductive surgery is combined with intraperitoneal c

163 However, primary cytoreductive surgery is preferred if there is a high li

164 As such, extensive cytoreductive surgery is required prior to IPC.

165 in metastatic melanoma tumors obtained from cytoreductive surgery of AJCC stage IV melanoma patients

166 r; however, a subset of patients who undergo cytoreductive surgery of distant metastases survive for

167 ree different ICT-containing strategies with cytoreductive surgery or biopsy for patients with metast

168 Patients receiving ICT with cytoreductive surgery or biopsy, did not experience addi

169 rent disease may be eligible for a secondary cytoreductive surgery or may require a surgical interven

170 randomly assigned to receive either interval cytoreductive surgery performed using MIS or laparotomy.

171 ecurrence develops are candidates for repeat cytoreductive surgery plus intraperitoneal chemotherapy

172 Cytoreductive surgery plus systemic chemotherapy may be

173 There is no known cure for PM and cytoreductive surgery remains controversial.

174 The impact on survival of secondary cytoreductive surgery requires more investigation.

175 We evaluated the effect of adding secondary cytoreductive surgery to postoperative chemotherapy on p

176 red to be maximal, the addition of secondary cytoreductive surgery to postoperative chemotherapy with

177 Primary cytoreductive surgery was associated with improved survi

178 h advanced ovarian carcinoma in whom primary cytoreductive surgery was considered to be maximal, the

179 tum, or peritoneal metastasis that underwent cytoreductive surgery were all excluded.

180 Histology, grade, stage, and success of cytoreductive surgery were similar for hereditary and sp

181 apy alone has recently been demonstrated for cytoreductive surgery when combined with intraoperative

182 ns were obtained from PM patients undergoing cytoreductive surgery with HIPEC.

183 5% CI, 18 to 32) in the group that underwent cytoreductive surgery with HIPEC.

184 During cytoreductive surgery with hyperthermic intraperitoneal

185 Cytoreductive surgery with hyperthermic intraperitoneal

186 e been made thanks to new techniques such as cytoreductive surgery with hyperthermic intraperitoneal

187 pre-existing database of patients undergoing cytoreductive surgery with hyperthermic intraperitoneal

188 Patient underwent cytoreductive surgery with residual disease and a pathol

189 t setting of patients who underwent complete cytoreductive surgery(CRS) for recurrent adult type gran

190 al has been met, with 43 patients completing cytoreductive surgery, 36 patients undergoing post-ICT b

191 Women who are fit for primary cytoreductive surgery, and with potentially resectable d

192 nt of advanced-stage ovarian cancer includes cytoreductive surgery, platinum-based chemotherapy, and

193 fluence the surgeon's decision on performing cytoreductive surgery, which may be followed by intraper

194 n with carboplatin and taxane regimens after cytoreductive surgery.

195 s for pathological assessment and for aiding cytoreductive surgery.

196 ase stage and visible residual disease after cytoreductive surgery.

197 were not considered candidates for complete cytoreductive surgery.

198 h the patient's clinical capacity to undergo cytoreductive surgery.

199 perioperative outcomes compared with primary cytoreductive surgery.

200 .7 months for patients who received ICT plus cytoreductive surgery.

201 e patient was treated with immunotherapy and cytoreductive surgery.

202 or recurrent ovarian cancer during secondary cytoreductive surgery.

203 spected ovarian cancer, scheduled to undergo cytoreductive surgery.

204 apy regimens with or without prior secondary cytoreductive surgery.

205 ement of immune responses following ICT plus cytoreductive surgery.

206 e either neoadjuvant chemotherapy or primary cytoreductive surgery.

207 18)F-FES PET/CT was performed shortly before cytoreductive surgery.

208 and hemodynamic findings when injected after cytoreductive surgery.

209 e a week either during tumor growth or after cytoreductive surgery.

210 up, disease stage, and timing and outcome of cytoreductive surgery.

211 The cytoreductive surgical procedures were sampled, and dise

212 With increasing radicality of cytoreductive surgical techniques and sophistication of

213 lliation (by excision and a variety of other cytoreductive techniques), they each are treated with an

214 ariable, there is greater potential need for cytoreductive therapies (eg, interferon-alpha, cladribin

215 antimediator therapies and consideration of cytoreductive therapies for those with treatment-refract

216 ia represents a major clinical problem after cytoreductive therapies such as chemotherapy and the con

217 Cytoreductive therapies, such as hydroxyurea or interfer

218 or venous thrombotic events compared with no cytoreductive therapy (3.6% vs 24%; P < .01).

219 Cytoreductive therapy aims to normalize platelet counts

220 cilitates hematopoietic reconstitution after cytoreductive therapy by: (1) delaying the exhaustion of

221 irst recurrence after chemotherapy, received cytoreductive therapy followed by high-dose etoposide, c

222 phlebotomy can constitute an indication for cytoreductive therapy in patients with otherwise low-ris

223 Prompt reconstitution of hematopoiesis after cytoreductive therapy is essential for patient recovery

224 Cytoreductive therapy prior to HSCT is advised for patie

225 Patients responding to cytoreductive therapy showed a significant decrease in K

226 samples from patients that had not undergone cytoreductive therapy were specifically chosen for COX i

227 peutic phlebotomy and aspirin alone, whereas cytoreductive therapy with either hydroxyurea or interfe

228 erive additional antithrombotic benefit from cytoreductive therapy with hydroxyurea as first-line and

229 with persistent PV symptoms may benefit from cytoreductive therapy with hydroxyurea or interferon to

230 d PV patients, PV patients who have received cytoreductive therapy, and healthy subjects.

231 lusively after successful induction of CR by cytoreductive therapy, followed either by donor lymphocy

232 In animals administered cytoreductive therapy, the use of TPO is associated with

233 r enhanced as in first-line therapy or after cytoreductive therapy.

234 oduced into tumor cells by viral vectors for cytoreductive therapy.

235 Most patients with ovarian cancer undergo cytoreductive therapy.

236 ous regimen-related toxicity after high-dose cytoreductive therapy.

237 rmal levels in the patients who had received cytoreductive therapy.

238 One patient was excluded due to concomitant cytoreductive therapy.

239 ss how symptom burden changes over time with cytoreductive therapy.

240 The latter might benefit from cytoreductive treatment before HCT.

241 gs can be administered to this purpose, with cytoreductive treatment being primarily given to patient

242 cal situations that would trigger the use of cytoreductive treatment for patients with low-risk PV as

243 ntithrombotic therapy for the thrombosis and cytoreductive treatment for the MPN.

244 lated interferon alfa-2a, is the recommended cytoreductive treatment for these patients.

245 immunocompetent adults) has always required cytoreductive treatment of recipients with irradiation o

246 anagrelide, approved immunomodulators, or no cytoreductive treatment).

247 hase III trial determining whether intensive cytoreductive treatment, followed by interferon consolid

248 nosine [2-CdA]) is a synthetic purine analog cytoreductive treatment, for which efficacy is mostly re

249 patients at high-risk of thrombosis require cytoreductive treatment, typically with hydroxycarbamide